Unknown

Dataset Information

0

Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.


ABSTRACT: Breast cancer (BC) is a molecularly heterogeneous disease that encompasses five major molecular subtypes (luminal A (LA), luminal B HER2 negative (LB-), luminal B HER2 positive (LB+), HER2 positive (HER2+) and triple negative breast cancer (TNBC)). BC treatment mainly depends on the identification of the specific subtype. Despite the correct identification, therapies could fail in some patients. Thus, further insights into the genetic and molecular status of the different BC subtypes could be very useful to improve the response of BC patients to the range of available therapies. In this way, we used gold nanoparticles (AuNPs, 12.96 ± 0.72 nm) as a scavenging tool in combination with Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS) to quantitatively analyze the serum proteome alterations in the different breast cancer intrinsic subtypes. The differentially regulated proteins specific of each subtype were further analyzed with the bioinformatic tools STRING and PANTHER to identify the major molecular function, biological processes, cellular origin, protein class and biological pathways altered due to the heterogeneity in proteome of the different BC subtypes. Importantly, a profile of blood coagulation proteins was identified in the serum of HER2-overexpressing BC patients.

SUBMITTER: Chantada-Vazquez MDP 

PROVIDER: S-EPMC7696934 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.

Chantada-Vázquez María Del Pilar MDP   Castro López Antonio A   García-Vence María M   Acea-Nebril Benigno B   Bravo Susana B SB   Núñez Cristina C  

International journal of molecular sciences 20201110 22


Breast cancer (BC) is a molecularly heterogeneous disease that encompasses five major molecular subtypes (luminal A (LA), luminal B HER2 negative (LB-), luminal B HER2 positive (LB+), HER2 positive (HER2+) and triple negative breast cancer (TNBC)). BC treatment mainly depends on the identification of the specific subtype. Despite the correct identification, therapies could fail in some patients. Thus, further insights into the genetic and molecular status of the different BC subtypes could be ve  ...[more]

Similar Datasets

| S-EPMC7061085 | biostudies-literature
| S-EPMC7052371 | biostudies-literature
| S-EPMC8804901 | biostudies-literature
| S-EPMC9267809 | biostudies-literature
| S-EPMC4125554 | biostudies-literature
| S-EPMC7254833 | biostudies-literature
| S-EPMC7788026 | biostudies-literature
| S-EPMC5901966 | biostudies-literature
| S-EPMC7150926 | biostudies-literature
| S-EPMC8127329 | biostudies-literature